Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension study of canakinumab vs triamcinolone for treatment and prevention of gout flares
2009-017503-29Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of canakinumab in gout and acute gout flare (2 arms), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability of canakinumab vs triamcinolone acetonide. Started Jan 2010; status: completed.
02
Drugs
canakinumab
03
Conditions
goutacute gout flare
Beyond the preview
Go deeper on 2009-017503-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017503-29.